Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
134.94
-1.04 (-0.76%)
At close: Apr 28, 2026, 4:00 PM EDT
134.92
-0.02 (-0.01%)
After-hours: Apr 28, 2026, 7:13 PM EDT
Insmed Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for Insmed stock have an average target of 201.17, with a low estimate of 120 and a high estimate of 245. The average target predicts an increase of 49.08% from the current stock price of 134.94.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Insmed stock from 24 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 12 | 12 | 13 | 13 |
| Buy | 7 | 9 | 10 | 9 | 10 | 10 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 21 | 24 | 23 | 24 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth Capital | Roth Capital | Strong Buy Reiterates $212 | Strong Buy | Reiterates | $212 | +57.11% | Apr 17, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $212 → $216 | Buy | Maintains | $212 → $216 | +60.07% | Apr 14, 2026 |
| Barclays | Barclays | Buy Maintains $231 → $237 | Buy | Maintains | $231 → $237 | +75.63% | Apr 1, 2026 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $166 → $212 | Hold → Buy | Upgrades | $166 → $212 | +57.11% | Mar 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $230 → $245 | Strong Buy | Maintains | $230 → $245 | +81.56% | Mar 26, 2026 |
Financial Forecast
Revenue This Year
1.71B
from 606.42M
Increased by 182.31%
Revenue Next Year
2.83B
from 1.71B
Increased by 65.19%
EPS This Year
-2.95
from -6.42
EPS Next Year
0.69
from -2.95
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.3B | 3.8B | ||||||
| Avg | 1.7B | 2.8B | ||||||
| Low | 949.6M | 1.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 282.2% | 120.4% | ||||||
| Avg | 182.3% | 65.2% | ||||||
| Low | 56.6% | 11.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.65 | 2.56 | ||||||
| Avg | -2.95 | 0.69 | ||||||
| Low | -5.02 | -1.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.